Regeneron Pharmaceuticals Change In Cash Over Time
| REGN Stock | USD 750.22 4.65 0.62% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Regeneron Pharmaceuticals Performance and Regeneron Pharmaceuticals Correlation. Regeneron |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.298 | Earnings Share 40.46 | Revenue Per Share 128.691 | Quarterly Revenue Growth 0.106 | Return On Assets 0.0741 |
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Change In Cash Analysis
Compare Regeneron Pharmaceuticals and related stocks such as Crispr Therapeutics, Novo Nordisk AS, and Sarepta Therapeutics Change In Cash Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CRSP | 584 K | 584 K | 584 K | 584 K | 584 K | 155 M | 159.6 M | (75.8 M) | 216.9 M | 489 M | 236.7 M | (245.5 M) | (715.9 M) | 177 M | 185.9 M |
| NVO | 212 M | 1.1 B | (2 B) | (540 M) | 3.2 B | 2.2 B | 2.6 B | (1.3 B) | (1.5 B) | (218 M) | (3.2 B) | (1.5 B) | 1.9 B | 1.7 B | 1.8 B |
| SRPT | (1.2 M) | 6.3 M | 147.8 M | 69.3 M | (183.4 M) | 6.8 M | 42.1 M | 477.3 M | (229 M) | 472.8 M | 668.1 M | 613.8 M | (1.1 B) | (541.8 M) | (514.7 M) |
| NTLA | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | 66 M | 197.2 M | 67.6 M | (281.8 M) | (1.6 M) | 107.4 M | (39.1 M) | 410 M | (295.1 M) | (280.4 M) |
| INCY | 14.9 M | (144.7 M) | (49.1 M) | 247.4 M | (19.1 M) | 69.1 M | 130.9 M | 247.2 M | 264.6 M | 668.7 M | (318.9 M) | 544.4 M | 894 M | 262.1 M | 275.2 M |
| ALNY | 17.3 M | (4.4 M) | (18.8 M) | 1.8 M | 22 M | 105.7 M | 12.7 M | 451.7 M | (224.2 M) | 127 M | (50.6 M) | 323.1 M | 46.4 M | (53.7 M) | (51 M) |
| UTHR | 22.9 M | (89.5 M) | (8.6 M) | 124.9 M | 113.4 M | 434.1 M | 191.2 M | (317.9 M) | (35.9 M) | 69.2 M | 300 K | 156.1 M | 66.4 M | 246.5 M | 258.8 M |
| RARE | 10.6 M | 10.6 M | 75.5 M | (78.8 M) | 16.9 M | 69.2 M | 67.6 M | (60.6 M) | 12.5 M | 320.7 M | 290.1 M | (416.7 M) | (172 M) | 81.8 M | 85.9 M |
| APLS | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 8.9 M | 22.4 M | (11.1 M) | 150.8 M | 624.1 K | 175.7 M | 215.1 M | 74.7 M | (88.7 M) | (200.8 M) | (190.7 M) |
| PTCT | (243.5 K) | (243.5 K) | (25.7 M) | 12.7 M | 34.3 M | 8.3 M | 299 K | 53.5 M | 57.7 M | 126 M | (79.2 M) | (19.1 M) | 98.7 M | 314.4 M | 330.1 M |
| KRYS | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 47.7 M | 54.1 M | 83.8 M | 80.8 M | 73 M | (179.3 M) | 196.4 M | 206.2 M |
| MDGL | 7.1 M | (1.2 M) | 51.4 M | (33 M) | (2.5 M) | (11.1 M) | 18.8 M | 129.5 M | (91.2 M) | (10.7 M) | 7.3 M | (17.7 M) | 295.3 M | (231.6 M) | (220.1 M) |
| BGNE | 3.3 M | 3.3 M | 3.3 M | 3.3 M | 10 M | 4 M | 69.6 M | 152.1 M | 501.1 M | (119.9 M) | 769.2 M | 3 B | (507.9 M) | (689.1 M) | (654.6 M) |
| BMRN | 3.4 M | (41.8 M) | 134.3 M | 388.3 M | 306.7 M | (478.4 M) | 11.3 M | 189.7 M | (104 M) | (56.5 M) | 211.7 M | (61.9 M) | 137.3 M | 30.6 M | 31.7 M |
| ARWR | 131 | (4.1 M) | 15.7 M | 113.4 M | (51.3 M) | 4.2 M | (60.5 M) | 5.3 M | 191.7 M | (78.2 M) | 40.9 M | (76.4 M) | 2.9 M | (12.4 M) | (11.8 M) |
| IONS | 64.5 M | (4.6 M) | 59 M | 35.5 M | (17 M) | (14.2 M) | (44.1 M) | 44.9 M | 149.2 M | 404.5 M | (285.6 M) | 471.5 M | (592.7 M) | 122.8 M | 128.9 M |
Regeneron Pharmaceuticals and related stocks such as Crispr Therapeutics, Novo Nordisk AS, and Sarepta Therapeutics Change In Cash description
My Equities
My Current Equities and Potential Positions
| Regeneron Pharmaceuticals | REGN |
| Classification | Biotech |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 750.22
Check out Regeneron Pharmaceuticals Performance and Regeneron Pharmaceuticals Correlation. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Regeneron Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.